Arthur Andrew Bavelas’ Post

Today LIVE in 1 hour: Lead investor Andreessen Horowitz (a16z) Bio + Health team in Arda Therapeutics joins us today for Family Office Insights Mercury Series Webinar featuring Adam Freund of Arda Therapeutics. Today: June 10 2024, 02:15 PM Eastern Time : RSVP: https://lnkd.in/gbTAiwpM Cells are the functional units of life. They are also the functional units of disease: many chronic diseases are caused by certain cell populations becoming too abundant or active. For example, subsets of stromal cells drives fibrosis, while the hyperactivity of particular immune cells leads to chronic inflammation. Arda Therapeutics is developing medicines to precisely remove these pathogenic cells, thereby treating diseases more effectively than by blocking individual proteins or signaling pathways. Their proprietary, single-cell-based discovery engine identifies pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.

“There have been a tremendous number of advances in new technologies, whether it's human genetics, single cell sequencing, and this has allowed us to define patient populations in very unique ways...for ultra-rare and rare diseases, we can now define patients not based upon a clinical phenotype or an individual mutation, but based upon shared biology and shared pathways. The flip side of this is that common diseases we can actually approach with a different level of precision that begins to resemble rare diseases,” explains Robert Plenge, Executive Vice President, Chief Research Officer, Head of Research, Bristol Myers Squibb. Catch the full panel conversation with Michelle Werner, Flagship CEO-Partner & CEO of Alltrna, Christopher Austin, Flagship CEO-Partner & CEO of Vesalius Therapeutics, and Jason Park, Flagship Operating Partner & CEO of Empress Therapeutics, for more on how these advancements and how #FlagshipFounded companies are pioneering treatments for rare and common diseases: https://bit.ly/3tXJqJ8 

There is still time to register for our upcoming rare disease webinar on February 27th! Advances in the understanding of rare disease biology, coupled with innovative technology and therapeutic platforms, have led to progress in the research and development of drugs for rare diseases. Despite these advances, many rare diseases still lack useful treatments and the need for new approaches remains high. In this webinar, we will discuss important trends in rare disease therapeutics and highlight ways of accelerating the drug discovery and development process. Don’t miss your chance to ask questions to our experts! Register Now by Clicking ⬇️ https://lnkd.in/eFDFddVw #RareDiseases #RareDiseaseDay #drugdiscovery #biotech #RareDiseaseDay2024

Tomorrow, our CEO Anker Lundemose will be at the Annual Seed🌱 Summit, the premier event welcomes portfolio companies, investors and pharma BD from across Europe and US for a full day of networking and discussions around company creation at the Novo Holdings HQ in Copenhagen. Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria which are significant drivers of disease pathophysiology in #acutekidneyinjury (#AKI), #ParkinsonsDisease (PD), #heartfailure, #DuchennesMuscularDystrophy (#DMD), #IPF, mitochondrial diseases and #alzheimers. Keep up to date with Mission Therapeutics by following us at Mission Therapeutics on LinkedIn or @MISSIONTherapeu on X / Twitter. You can also visit our website using the link in the comments below. #NovoHoldings #mitophagy #DUBInhibitors #parkinsons #alzheimersdisease

Here is a brief glimpse into the work I do in the world of biologic drug development. What are biologic drugs and why are they important in the fight against cancer and other diseases? Find out how biologic medicines provide more treatment options for people who suffer from untreated or undertreated conditions, and discover Teva’s innovative work in this space: https://lnkd.in/gkjMjswm

Now available to view on demand! In our latest webinar, experts discuss important trends in rare disease therapeutics and highlight ways of accelerating the drug discovery and development process. Strategies such as enzyme replacement therapy, cell therapy, and oligonucleotide therapeutics have created a diverse toolbox for tailored interventions, leading to an increase in drug approvals. This webinar provides a comprehensive and stimulating perspective for the many research teams committed to increasing drug accessibility for people living with rare diseases. Questions? Contact us here: https://lnkd.in/eG97YXCs #RareDiseases #ERT #CellTherapy #Oligonucleotides #Fabry #Gaucher #Pompe #Biotech #DrugDiscovery Curious to learn more? View the video now by clicking 👇 https://lnkd.in/gi6-gSqj

Marea Therapeutics Launches With $190 Million To Transform Cardiometabolic Disease Treatment Learn more & get our take 👇 https://lnkd.in/gqJvcckA “Marea aims to transform the way cardiometabolic diseases are treated by leveraging large-scale human genetics and expertise in adipose function and biology to pursue genetically validated targets focusing on central – but unaddressed – drivers of cardiometabolic disease risk.” — Josh Lehrer, M.D., M.Phil., FACC, CEO at Marea Therapeutics “With initial clinical validation, world-class scientific founders and investors, and an experienced board and leadership team, Marea is poised to become a premier cardiometabolic disease company.” — Jeffrey Tong, Ph.D., Board Member and Partner at Third Rock Ventures “MAR001 has the potential to provide unique benefit to these patients by correcting the underlying adipose dysfunction leading to both elevated remnant cholesterol and metabolic dysfunction.” — Ethan Weiss, M.D., Co-founder and Chief Scientific Officer at Marea Therapeutics “In a Phase 1 trial, a single dose of MAR001 significantly lowered remnant cholesterol levels and improved metabolic biomarkers. We are very excited about this compound’s potential. Led by renowned experts in genetics and cardiometabolic diseases, Marea is well positioned to advance MAR001 and other pipeline programs, potentially unlocking a new era in cardiovascular care.” — Maha Katabi, PhD, CFA, Ph.D., General Partner at Sofinnova Investments #funding #therapeutics #SoHCNews

Arovella Therapeutics ASX: ALA released additional data supporting its CAR-iNKT program today. ★ New data utilising a different CAR-iNKT product, manufactured using Arovella’s platform, supports the extended use of the CAR-iNKT cell platform against multiple tumour types ★ Superior animal survival data from Arovella’s CAR-iNKT Platform with CD28 co-stimulatory domain ★ Data presented at the 65th American Society of Hematology (ASH) annual meeting in San Diego, California The data used the ALA platform to produce CAR-iNKT cells targeting B-cell maturation antigen (BCMA) to eliminate #multiplemyeloma and describes the optimisation of the CAR construct. The work identified that the CD28 co-stimulatory domain was more effective than other co-stimulatory domains and led to substantially improved anti-tumour activity in mice. This CD28 co-stimulatory domain is also incorporated into Arovella’s ALA-101 product. The video of the presentation is below. #biotechnology #cancercure #tumor #bloodcancer #smallcap

Excited to share that Candid Therapeutics has officially entered the biotech scene with a whopping $370m to develop T cell engager (TCE) antibodies! Their focus? Tackling inflammatory diseases by targeting and depleting specific B lymphocyte populations. This approach has already shown promise in conditions like rheumatoid arthritis and myasthenia gravis which is positive. Candid's strategy is backed by heavyweights like Venrock Healthcare Capital Partners, Fairmount, TCGX, and more. With candidates like CND106 and CD20xCD3 from Phase I trials already in their portfolio, they are hitting the ground running. This looks set to be a game-changer in autoimmune disease treatment. #CandidTherapeutics #AutoimmuneDisease #Biotechnology #PharmaTech #LifeSciences #Innovation #ClinicalResearch #ClinicalTrials #ElixirAssociates #StaffingPartner

Are you looking to test your drugs, antibodies, or cells against cancers and other diseases? Look no further than Oncoseek Bio! We're at the forefront of developing cutting-edge in vitro alternatives to animal testing. Our custom-built in vitro models are FDA/CDSCO/EU compliant and tailored to fit your research programs. Plus, our novel Spheroid/Organoid models made from primary cells, patient-derived cells, or basic cell lines can help you cut costs in testing your new compounds for toxicity or efficacy. Reach out to us today to learn more about our capabilities and schedule a meeting. #invitro #drugtesting #cancertreatment #biotech #3dprinting #drugdiscovery #antibody #celltherapy #cro #alternatives